Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Abstract Background Previous studies have demonstrated that left-sided tumors have better prognoses than right-sided tumors in RAS wild-type mCRC (metastatic colorectal cancer) patients, while anti-EGFR mAbs appear to have no advantage compared with bevacizumab for right-sided tumors in these patien...

Full description

Bibliographic Details
Main Authors:	Datian Chen, Xiang Zhang, Guangyi Gao, Lili Shen, Jiaqi Xie, Xiaoping Qian, Huiyu Wang
Format:	Article
Language:	English
Published:	BMC 2018-10-01
Series:	World Journal of Surgical Oncology
Subjects:	Metastatic colorectal cancer Primary tumor location Anti-EGFR mAb Resection Conversion therapy
Online Access:	http://link.springer.com/article/10.1186/s12957-018-1502-7

Similar Items

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
by: Chen DT, et al.
Published: (2019-02-01)

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
by: Cinzia Vetrei, et al.
Published: (2021-12-01)

Implementation of QbD strategies in the inoculum expansion of a mAb production process
by: Ole Jacob Böhl, et al.
Published: (2021-03-01)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
by: Qiuxia Qu, et al.
Published: (2020-04-01)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-04-01)

Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg
by: Mepur H. Ravindranath, et al.
Published: (2021-06-01)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
by: Annabel H. S. Alig, et al.
Published: (2022-01-01)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
by: Josée Golay, et al.
Published: (2020-10-01)

An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunction
by: Zhonglin Liu, et al.
Published: (2024-01-01)

Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly
by: Mercè Farràs, et al.
Published: (2020-01-01)

Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus
by: Mengjun Li, et al.
Published: (2023-12-01)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
by: Margherita Passariello, et al.
Published: (2020-08-01)

How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca<sup>2+</sup>
by: Ronald P. Taylor, et al.
Published: (2020-09-01)

Monoclonal Antibody Therapies against Anthrax
by: Zhaochun Chen, et al.
Published: (2011-08-01)

Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 mAb and Its Efficacy Assessments by Molecular Imaging
by: Jun Zhou, et al.
Published: (2019-11-01)

Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
by: Nikolaj Siersbæk, et al.
Published: (2023-07-01)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
by: Cinzia Vetrei, et al.
Published: (2021-06-01)

Concentration Effects in the Interaction of Monoclonal Antibodies (mAbs) with their Immediate Environment Characterized by EPR Spectroscopy
by: Haleh H. Haeri, et al.
Published: (2019-07-01)

Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
by: Cristina Capuano, et al.
Published: (2021-05-01)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
by: Rosa Rapuano Lembo, et al.
Published: (2022-10-01)

Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal
by: Yan Tereshko, et al.
Published: (2023-11-01)

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review
by: Jingyuan Shang, et al.
Published: (2022-08-01)

Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery
by: Kelly Schwinghamer, et al.
Published: (2023-10-01)

Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy
by: Laura Orellana
Published: (2019-09-01)

Ovarian cancer cells direct monocyte differentiation through a non-canonical pathway
by: Kaitlin C. Fogg, et al.
Published: (2020-10-01)

Ranking mAb–excipient interactions in biologics formulations by NMR spectroscopy and computational approaches
by: Chunting Zhang, et al.
Published: (2023-12-01)

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
by: Masaud Shah, et al.
Published: (2020-01-01)

Adhesion Molecule Profile and the Effect of Anti-VLA-4 mAb Treatment in Experimental Autoimmune Encephalomyelitis, a Mouse Model of Multiple Sclerosis
by: Grażyna Pyka-Fościak, et al.
Published: (2022-04-01)

Winnaars MAB-scriptieprijs 2023 bekend
by: Annemarie Oord
Published: (2023-12-01)

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab
by: Margherita Passariello, et al.
Published: (2022-05-01)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
by: Bianca Raffaelli, et al.
Published: (2023-02-01)

Engineering death resistance in CHO cells for improved perfusion culture
by: Michael A. MacDonald, et al.
Published: (2022-12-01)

Ab locks for improving the selectivity and safety of antibody drugs
by: Wen-Wei Lin, et al.
Published: (2020-06-01)

Process control of mAb production using multi-actor proximal policy optimization
by: Nikita Gupta, et al.
Published: (2023-09-01)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
by: Bruce D. Wines, et al.
Published: (2021-10-01)

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors
by: Zhiyu Huang, et al.
Published: (2023-10-01)

M.A.B. Revestimientos vítreos con propiedades bactericidas y fungicidas
by: Yagüe Muñoz, A., et al.
Published: (2012-04-01)

Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections
by: Pardis Mokhtary, et al.
Published: (2022-08-01)

The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus
by: Yongcheng Duan, et al.
Published: (2023-11-01)